Title : The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.

Pub. Date : 2017 Nov

PMID : 28331226






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. givinostat cytokine receptor like factor 2 Homo sapiens
2 Here, we found that givinostat inhibited proliferation and induced apoptosis of BCP-ALL CRLF2-rearranged cell lines, positive for exon 16 JAK2 mutations. givinostat cytokine receptor like factor 2 Homo sapiens
3 Lastly, the selective killing of cancer cells by givinostat may allow the design of reduced intensity regimens in CRLF2-rearranged Down syndrome-associated BCP-ALL patients with an overall benefit in terms of both toxicity and related complications. givinostat cytokine receptor like factor 2 Homo sapiens